News
These include therapeutic antibodies like ABX-IL-8 and HuMax-IL-8 (BMS-986253), CXCR1/CXCR2 inhibitors, and p38 MAPK inhibitors. The authors emphasize the importance of addressing potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback